4 Healthcare Stock Stories Offering Investment Wellness Today
Eli Lilly and Co. (NYSE:LLY): Closing price $51.04
On Thursday, Lilly announced that its experiment cancer drug ramucirumab did not meet its target in a large late-stage study testing it as a front-line treatment for breast cancer. The firm is testing ramucirumab on several types of tumors, among which include colon, liver, and lung cancer. In a separate late-stage evaluation released Thursday, ramucirumab improved the overall survival in patients suffering from stomach cancer, which is a large international market. Lilly intends to file for regulatory approval for gastric cancer and approval could come next year, but the setback in breast cancer is forcing analysts to reduce sales forecasts for the drug.